March 14, 2011 – Sorin Group has reached a major milestone with the 100,000th MitroFlow Aortic Pericardial Heart Valve implantation worldwide.
Aortic valve replacement is the most effective treatment for aortic valve diseases, improving survival rates and quality of life. The pericardial valve is able to fully replace a malfunctioning or diseased aortic heart valve, offering an effective choice for patients and surgeons.
Since its introduction in Europe in 1982, the device has demonstrated excellent hemodynamic performance and proven long-term durability. Due to its design, supported by nearly 30 years of clinical use and 21 years of published long-term results, the valve is recognized by surgeons worldwide for its versatility and ease of implant, even in the most challenging anatomies.
“Our clinical experience with over 1,900 implants with the Mitroflow Aortic Pericardial Heart Valve has shown the valve’s exceptional durability, one of the longest on the market. This can be attributed to its special design, easy implantability and excellent hemodynamic characteristics. Mitroflow has provided assurance to a wide variety of patients who prefer or require biological valve implantation,” said Charles Yankah, associate professor of surgery, Charité Medical University and consultant CardioThoracic and vascular surgeon, German Heart Institute in Berlin, Germany.
For more information: www.sorin.com
March 25, 2026 
